Michael Robert Ballinger

Array ( [id] => 20593583 [patent_doc_number] => 12577285 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-17 [patent_title] => Process for producing a composition of engineered T cells [patent_app_type] => utility [patent_app_number] => 16/769971 [patent_app_country] => US [patent_app_date] => 2018-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 15 [patent_no_of_words] => 154997 [patent_no_of_claims] => 53 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 408 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16769971 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16504767 [patent_doc_number] => 20200384023 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-10 [patent_title] => Antibody Or Antigen Binding Fragment Thereof For Specifically Recognizing B Cell Malignancy, Chimeric Antigen Receptor Comprising Same And Use Thereof [patent_app_type] => utility [patent_app_number] => 16/768412 [patent_app_country] => US [patent_app_date] => 2018-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14916 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16768412 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18384525 [patent_doc_number] => 11655297 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-23 [patent_title] => ILDR2 antagonists and combinations thereof [patent_app_type] => utility [patent_app_number] => 16/766224 [patent_app_country] => US [patent_app_date] => 2018-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 11 [patent_no_of_words] => 13481 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16766224 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16483998 [patent_doc_number] => 20200377599 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-03 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 16/767487 [patent_app_country] => US [patent_app_date] => 2018-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17055 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16767487 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16451006 [patent_doc_number] => 20200360432 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-19 [patent_title] => POLYPEPTIDE [patent_app_type] => utility [patent_app_number] => 16/766128 [patent_app_country] => US [patent_app_date] => 2018-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8045 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16766128 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16466988 [patent_doc_number] => 20200368525 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-26 [patent_title] => Methods of Treating Glioblastoma [patent_app_type] => utility [patent_app_number] => 16/764248 [patent_app_country] => US [patent_app_date] => 2018-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7019 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16764248 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18340451 [patent_doc_number] => 20230132400 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2023-04-27 [patent_title] => COMBINATION THERAPY FOR TREATMENT OF A HEMATOLOGICAL DISEASE [patent_app_type] => utility [patent_app_number] => 16/755589 [patent_app_country] => US [patent_app_date] => 2018-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12308 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16755589 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18340451 [patent_doc_number] => 20230132400 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2023-04-27 [patent_title] => COMBINATION THERAPY FOR TREATMENT OF A HEMATOLOGICAL DISEASE [patent_app_type] => utility [patent_app_number] => 16/755589 [patent_app_country] => US [patent_app_date] => 2018-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12308 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16755589 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16420578 [patent_doc_number] => 20200345776 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => CELL [patent_app_type] => utility [patent_app_number] => 16/763539 [patent_app_country] => US [patent_app_date] => 2018-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12029 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16763539 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16900798 [patent_doc_number] => 20210179714 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-17 [patent_title] => Inhibition of CTLA-4 and/or PD-1 For Regulation of T Cells [patent_app_type] => utility [patent_app_number] => 16/761784 [patent_app_country] => US [patent_app_date] => 2018-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18984 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16761784 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18151996 [patent_doc_number] => 11564946 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-31 [patent_title] => Methods associated with tumor burden for assessing response to a cell therapy [patent_app_type] => utility [patent_app_number] => 16/760382 [patent_app_country] => US [patent_app_date] => 2018-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 71779 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16760382 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17697133 [patent_doc_number] => 11370844 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-28 [patent_title] => Anti-CD5L antibody and uses thereof [patent_app_type] => utility [patent_app_number] => 16/760179 [patent_app_country] => US [patent_app_date] => 2018-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 6 [patent_no_of_words] => 14355 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16760179 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16343630 [patent_doc_number] => 20200308280 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => METHODS FOR CANCER TREATMENT USING A RADIOLABELED ANTI-CD45 IMMUNOGLOBULIN AND ADOPTIVE CELL THERAPIES [patent_app_type] => utility [patent_app_number] => 16/754400 [patent_app_country] => US [patent_app_date] => 2018-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16920 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16754400 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16238293 [patent_doc_number] => 20200255527 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 16/758474 [patent_app_country] => US [patent_app_date] => 2018-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25206 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16758474 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17784721 [patent_doc_number] => 11407833 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-09 [patent_title] => Anti-VISTA antibody and use thereof [patent_app_type] => utility [patent_app_number] => 16/757156 [patent_app_country] => US [patent_app_date] => 2018-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 10 [patent_no_of_words] => 14374 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 751 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16757156 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16809487 [patent_doc_number] => 20210132041 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => TARGET FOR DRUG TREATMENT OF TUMOR METASTASIS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/041917 [patent_app_country] => US [patent_app_date] => 2018-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4934 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17041917 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18274650 [patent_doc_number] => 11613581 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-28 [patent_title] => Antibodies and antibody-drug conjugates specific for CD123 and uses thereof [patent_app_type] => utility [patent_app_number] => 16/758124 [patent_app_country] => US [patent_app_date] => 2018-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 26667 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16758124 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16359371 [patent_doc_number] => 20200316122 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-08 [patent_title] => METHODS OF PRODUCING T CELL POPULATIONS USING P38 MAPK INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/754926 [patent_app_country] => US [patent_app_date] => 2018-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11123 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16754926 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16420591 [patent_doc_number] => 20200345789 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => PRODUCTION METHOD FOR IPS CELL-DERIVED POPULATION OF GENETICALLY DIVERSE T CELLS [patent_app_type] => utility [patent_app_number] => 16/652011 [patent_app_country] => US [patent_app_date] => 2018-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7534 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16652011 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16206569 [patent_doc_number] => 20200239559 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => ANTI IGF, ANTI PD-1, ANTI-CANCER COMBINATION THERAPY [patent_app_type] => utility [patent_app_number] => 16/649763 [patent_app_country] => US [patent_app_date] => 2018-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12005 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16649763 [rel_patent_id] =>[rel_patent_doc_number] =>)